PL1904056T3 - Zastosowanie makrolidu do przywracania czucia rogówkowego - Google Patents

Zastosowanie makrolidu do przywracania czucia rogówkowego

Info

Publication number
PL1904056T3
PL1904056T3 PL06787603T PL06787603T PL1904056T3 PL 1904056 T3 PL1904056 T3 PL 1904056T3 PL 06787603 T PL06787603 T PL 06787603T PL 06787603 T PL06787603 T PL 06787603T PL 1904056 T3 PL1904056 T3 PL 1904056T3
Authority
PL
Poland
Prior art keywords
macrolide
corneal sensation
restore corneal
restore
sensation
Prior art date
Application number
PL06787603T
Other languages
English (en)
Inventor
Gholam A Peyman
Original Assignee
Minu Llc
Optivue L L P
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/183,355 external-priority patent/US20070014760A1/en
Application filed by Minu Llc, Optivue L L P filed Critical Minu Llc
Publication of PL1904056T3 publication Critical patent/PL1904056T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2093—Leukaemia inhibitory factor [LIF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL06787603T 2005-07-18 2006-07-18 Zastosowanie makrolidu do przywracania czucia rogówkowego PL1904056T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/183,355 US20070014760A1 (en) 2005-07-18 2005-07-18 Enhanced recovery following ocular surgery
US11/263,737 US20070015697A1 (en) 2005-07-18 2005-11-01 Enhanced ocular neuroprotection and neurostimulation
PCT/US2006/027713 WO2007011880A2 (en) 2005-07-18 2006-07-18 Enhanced ocular neuroprotection/neurostimulation
EP06787603A EP1904056B1 (en) 2005-07-18 2006-07-18 Use of a macrolide to restore corneal sensation

Publications (1)

Publication Number Publication Date
PL1904056T3 true PL1904056T3 (pl) 2009-09-30

Family

ID=37669471

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06787603T PL1904056T3 (pl) 2005-07-18 2006-07-18 Zastosowanie makrolidu do przywracania czucia rogówkowego

Country Status (6)

Country Link
US (3) US7833966B2 (pl)
EP (1) EP1904056B1 (pl)
AU (1) AU2006270041B2 (pl)
CA (1) CA2615990A1 (pl)
PL (1) PL1904056T3 (pl)
WO (1) WO2007011880A2 (pl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7837719B2 (en) * 2002-05-09 2010-11-23 Daemen College Electrical stimulation unit and waterbath system
JP2007505932A (ja) 2003-09-18 2007-03-15 マクサイト, インコーポレイテッド 経強膜送達
CA2597590A1 (en) 2005-02-09 2006-08-17 Macusight, Inc. Formulations for ocular treatment
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
KR101478164B1 (ko) 2006-02-09 2014-12-31 산텐 세이야꾸 가부시키가이샤 안정한 제제와 그 제조 및 사용 방법
AU2007230964B2 (en) 2006-03-23 2012-07-19 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
US20080146497A1 (en) * 2006-07-25 2008-06-19 Graham Richard S Cyclosporin Compositions
US9561178B2 (en) 2006-07-25 2017-02-07 Allergan, Inc. Cyclosporin compositions
EP2139492A1 (en) 2007-03-30 2010-01-06 Fovea Pharmaceuticals SA Methods for treating neovascular ocular diseases
CN101687013A (zh) * 2007-05-04 2010-03-31 阿勒根公司 环孢菌素在治疗具有人工晶状体的患者中的用途
JP5668476B2 (ja) 2007-10-08 2015-02-12 オーリニア・ファーマシューティカルズ・インコーポレイテッドAurinia Pharmaceuticals Inc. カルシニューリン阻害剤またはmTOR阻害剤を含む眼科用組成物
US20090131303A1 (en) * 2007-11-16 2009-05-21 Bor-Shyue Hong Methods and compositions for treating dry eye
WO2009114010A1 (en) * 2008-03-11 2009-09-17 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
US7678078B1 (en) * 2008-10-21 2010-03-16 KMG Pharma LLC Intravitreal injection device, system and method
US20100158821A1 (en) * 2008-12-22 2010-06-24 Eastman Chemical Company Antimicrobial agents, compositions and products containing the same, and methods of using the compositions and products
US20110009339A1 (en) * 2009-04-14 2011-01-13 Allergan, Inc Method of treating blurred vision and other conditions of the eye with cyclosporin compositions
US8106111B2 (en) * 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
EP2440185B1 (en) * 2009-06-09 2015-04-08 Aurinia Pharmaceuticals Inc. Topical drug delivery systems for ophthalmic use
US20120177741A1 (en) * 2009-09-29 2012-07-12 Eyegate Pharmaceuticals, Inc. Positively-charged poly (d,l-lactide-co-glycolide) nanoparticles and fabrication methods of the same
US20130066283A1 (en) * 2009-10-23 2013-03-14 Nexisvision, Inc. Corneal Denervation for Treatment of Ocular Pain
US9011861B2 (en) * 2010-02-25 2015-04-21 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
US20120003296A1 (en) * 2010-07-01 2012-01-05 Shantha Totada R New methods of treating dry eye syndrome
US20120156202A1 (en) * 2010-11-05 2012-06-21 Shantha Totada R Age related macular degeneration treatment
PL2887923T3 (pl) 2012-08-24 2023-08-14 Sun Pharmaceutical Industries Limited Preparat okulistyczny polioksylipidu lub polioksylowego kwasu tłuszczowego i leczenie chorób oczu
FR2997079B1 (fr) * 2012-10-24 2015-01-23 Michelin & Cie Polyamine polyaromatique soufree utilisable pour la synthese de polyuree
WO2015179527A1 (en) * 2014-05-23 2015-11-26 Ocular Technologies Sarl Topical formulations and uses thereof
DK3373976T3 (da) 2015-11-10 2024-04-02 Sun Pharmaceutical Ind Ltd Topiske formuleringer og anvendelser deraf
ITUB20169937A1 (it) 2016-01-12 2017-07-12 Medical And Biotechnological Services In Sigla M B S Srl Formulazioni farmaceutiche e loro uso per il trattamento della retinite pigmentosa
NZ785158A (en) 2016-02-29 2025-03-28 Sun Pharmaceutical Ind Ltd Topical cyclosporine-containing formulations and uses thereof
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
US11786694B2 (en) 2019-05-24 2023-10-17 NeuroLight, Inc. Device, method, and app for facilitating sleep
WO2021186041A1 (en) * 2020-03-19 2021-09-23 Universität Rostock Josamycin for use in prevention and treatment of fibrosis
CN117462653B (zh) * 2023-11-28 2024-08-30 山东第一医科大学附属眼科研究所(山东省眼科研究所、山东第一医科大学附属青岛眼科医院) 抑瘤素m在制备促进角膜上皮损伤修复的药物中的应用
WO2025260023A1 (en) * 2024-06-14 2025-12-18 Spiral Therapeutics, Inc. Methods of treating otic disorders

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4131648A (en) * 1975-01-28 1978-12-26 Alza Corporation Structured orthoester and orthocarbonate drug delivery devices
US4093709A (en) * 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4180646A (en) * 1975-01-28 1979-12-25 Alza Corporation Novel orthoester polymers and orthocarbonate polymers
US4079038A (en) * 1976-03-05 1978-03-14 Alza Corporation Poly(carbonates)
US4304767A (en) * 1980-05-15 1981-12-08 Sri International Polymers of di- (and higher functionality) ketene acetals and polyols
JP2577049B2 (ja) 1987-06-04 1997-01-29 三共株式会社 シクロスポリン製剤
WO1989001772A1 (en) 1987-09-03 1989-03-09 University Of Georgia Research Foundation, Inc. Ocular cyclosporin composition
US4946931A (en) * 1989-06-14 1990-08-07 Pharmaceutical Delivery Systems, Inc. Polymers containing carboxy-ortho ester and ortho ester linkages
ZA905202B (en) 1989-07-05 1991-04-24 Fujisawa Pharmaceutical Co Aqueous liquid composition for external use
US5294604A (en) 1989-12-20 1994-03-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating ocular diseases by periocular administration of cyclosporine A or G
ZA924953B (en) 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
JPH0710752A (ja) 1993-06-23 1995-01-13 Tokushu Meneki Kenkyusho:Kk アレルギー性及び自己免疫疾患治療用新規医薬組成物
US5788687A (en) 1994-02-01 1998-08-04 Caphco, Inc Compositions and devices for controlled release of active ingredients
US5457182A (en) 1994-02-15 1995-10-10 Merck & Co., Inc. FK-506 cytosolic binding protein, FKBP12.6
US6179817B1 (en) 1995-02-22 2001-01-30 Boston Scientific Corporation Hybrid coating for medical devices
US6413536B1 (en) * 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
JPH0930966A (ja) 1995-07-24 1997-02-04 Gakuzo Tamura 眼科用新規製剤
US5773019A (en) 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5968543A (en) * 1996-01-05 1999-10-19 Advanced Polymer Systems, Inc. Polymers with controlled physical state and bioerodibility
JP2000507997A (ja) 1996-02-09 2000-06-27 サーフェス ソルーションズ ラボラトリーズ インコーポレイテッド 水性の親水性被覆組成物及びそれから製造した物品
ES2243978T3 (es) 1996-02-13 2005-12-01 G.D. SEARLE & CO. Composiciones que comprenden un inhibidor de la ciclooxigenasa-2 y un antagonista del receptor de leucotrieno b4.
JPH09315954A (ja) 1996-05-30 1997-12-09 Kita:Kk 眼科手術後の眼組織混濁防止剤。
WO1998010785A1 (en) * 1996-09-13 1998-03-19 Advanced Medicine Research Institute Ophthalmic compositions of neurotrophic factors, remedies for optic nerve function disorders and method for treating optic nerve function disorders
US5952371A (en) 1996-10-16 1999-09-14 Merck & Co., Inc. Triterpene derivatives with immunosuppressant activity
AUPO427196A0 (en) 1996-12-19 1997-01-23 University Of Sydney, The A method for preventing or controlling cataract
JPH10218787A (ja) 1997-02-06 1998-08-18 Akio Okamoto 神経栄養因子による眼科用組成物
US6670398B2 (en) 1997-05-14 2003-12-30 Atherogenics, Inc. Compounds and methods for treating transplant rejection
US20030181692A1 (en) 1997-06-06 2003-09-25 Jian Ni 207 human secreted proteins
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
US6015815A (en) * 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
AR043071A1 (es) 1997-10-31 2005-07-20 Abbott Lab Uso de macrolidos para el tratamiento del cancer y degeneracion macular y una composicion farmaceutica
CZ287497B6 (cs) 1997-12-30 2000-12-13 Galena, A. S. Topické oční přípravky s imunosupresivními látkami
JP2002503692A (ja) 1998-02-23 2002-02-05 藤沢薬品工業株式会社 マクロライド系化合物の緑内障治療用途
DE19810655A1 (de) 1998-03-12 1999-09-16 Univ Eberhard Karls Arzneimittel mit einem Gehalt an Ciclosporin
JP2002509555A (ja) 1998-04-06 2002-03-26 藤沢薬品工業株式会社 新規用途
TR200003108T2 (tr) 1998-04-27 2001-02-21 Fujisawa Pharmaceutical Co., Ltd. İlaç kompozisyonları
US6218423B1 (en) * 1998-08-14 2001-04-17 Gpi Nil Holdings, Inc. Pyrrolidine derivatives for vision and memory disorders
US6864232B1 (en) 1998-12-24 2005-03-08 Sucampo Ag Agent for treating visual cell function disorder
US6462071B1 (en) 2000-03-02 2002-10-08 Vitreo-Retinal Technologies, Inc. Agents for intravitreal administration to treat or prevent disorders of the eye
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
CZ20013769A3 (cs) 1999-04-30 2002-03-13 Sucampo Ag Činidlo pro léčbu suchého oka
US7063857B1 (en) 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
US6482799B1 (en) 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
CA2379909C (en) * 1999-08-06 2011-01-04 Board Of Regents, The University Of Texas System Drug releasing biodegradable fiber implant
JP2001064198A (ja) 1999-08-24 2001-03-13 Teika Seiyaku Kk 角膜疾患治療剤
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US6489335B2 (en) 2000-02-18 2002-12-03 Gholam A. Peyman Treatment of ocular disease
PT1142566E (pt) * 2000-04-07 2004-02-27 Medidom Lab Formulacao oftalmica topica na forma de uma solucao aquosa e uso de uma ciclosporina em associacao com acido hialuronico ou um de seus sais e com polisorbato 80
US6613355B2 (en) * 2000-05-11 2003-09-02 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
CN1127955C (zh) 2000-07-07 2003-11-19 中山医科大学中山眼科中心 一种眼前段及眼表免疫相关性疾病治疗药物
CN1204919C (zh) 2000-08-30 2005-06-08 中国科学院化学研究所 长效环孢素眼内释药体系
AU2001292881A1 (en) 2000-09-20 2002-04-02 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US6534693B2 (en) 2000-11-06 2003-03-18 Afmedica, Inc. Surgically implanted devices having reduced scar tissue formation
US6440942B1 (en) * 2000-12-22 2002-08-27 Enanta Pharmaceuticals, Inc. 14-membered macrolides derived from leucomycins
US6462026B1 (en) * 2001-02-16 2002-10-08 Enanta Pharmaceuticals, Inc. Bicyclic leucomycins
US6713081B2 (en) 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
US6436906B1 (en) * 2001-04-02 2002-08-20 Enanta Pharmaceuticals, Inc. 9-amino-14-membered macrolides derived from leucomycins
JP4588979B2 (ja) 2001-04-20 2010-12-01 オプタルモファーマ アクチェンゲゼルシャフト プロドラッグとして使用されうる修飾型シクロスポリン及びその使用
TWI324925B (en) 2001-08-23 2010-05-21 Novartis Ag Ophthalmic composition
US6524606B1 (en) * 2001-11-16 2003-02-25 Ap Pharma, Inc. Bioerodible polyorthoesters containing amine groups
US20030129164A1 (en) * 2001-12-03 2003-07-10 Flannery John G. Expression of glial-derived neurotrophic factor for treatment of diseases of the eye
MXPA04005783A (es) 2001-12-14 2004-09-13 Jagotec Ag Formulacion farmaceutica que comprende ciclosporina y uso de la misma.
CN1456350A (zh) 2002-05-10 2003-11-19 刘继东 环孢素眼用凝胶
US20040162315A1 (en) * 2002-07-23 2004-08-19 Hellberg Mark R. Use of compounds for treating conditions resulting from injury to the corneal nerve after LASIK and other ocular surgeries or trauma
BR0313425A (pt) 2002-08-09 2005-07-05 Sucampo Pharmaceuticals Inc Composição oftálmica para tratamento de alergia ocular, uso do composto de macrolìdeo e pacote comercial
SI1539157T1 (sl) 2002-09-18 2013-11-29 Trustees Of The University Of Pennsylvania Rapamicin za uporabo pri inhibiciji ali preprečevanju horoidalne neovaskularizacije
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
AU2003228126A1 (en) 2003-05-02 2004-11-23 Arturo Jimenez Bayardo Method of preparing an aqueous solution of cyclosporin-a and resulting aqueous solution
US7083802B2 (en) * 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
JP2007505932A (ja) 2003-09-18 2007-03-15 マクサイト, インコーポレイテッド 経強膜送達
US7083803B2 (en) * 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US20050256065A1 (en) * 2004-01-26 2005-11-17 Permasight Method for stabilizing changes in corneal curvature in an eye by administering compositions containing stabilizing ophthalmic agents

Also Published As

Publication number Publication date
US20110039790A1 (en) 2011-02-17
WO2007011880A3 (en) 2007-06-21
AU2006270041B2 (en) 2011-08-18
US7833966B2 (en) 2010-11-16
US8202840B2 (en) 2012-06-19
EP1904056A2 (en) 2008-04-02
AU2006270041A1 (en) 2007-01-25
US20080108579A1 (en) 2008-05-08
EP1904056B1 (en) 2009-04-29
CA2615990A1 (en) 2007-01-25
WO2007011880A2 (en) 2007-01-25
US20070078077A1 (en) 2007-04-05

Similar Documents

Publication Publication Date Title
PL3424932T3 (pl) Boronoftalidy do zastosowania terapeutycznego
CY2014030I1 (el) Θεραπευτικες συνθεσεις που περιλαμβανουν ingenol-3-angelate
EP1962961A4 (en) DEMIKÖRPER: DIMERIZATION-ACTIVATED THERAPEUTIC AGENT
DK1720866T3 (da) Fremgangsmåde
HRP20190084T1 (hr) Injektibilne paraziticidne formulacije s produljenim djelovanjem
FI20060708L (fi) Hierontalaite
EP1868459A4 (en) FUNCTIONAL SHOE
BRPI0614464A2 (pt) preparação cosmética
JP2006122056A5 (ja) β-グルカンの使用
DK1863899T3 (da) Hudbehandlingspræparater
BRPI0818121A2 (pt) diespiro 1,2,4-trioxolano e seus métodos de fabricação e utilização
BRPI0810475A2 (pt) uso de dimiracetam no tratamento de dor crônica
BRPI0616297A2 (pt) bandagem de espuma
DK2119472T3 (da) Hud-/hårbehandlingssystem
BRPI0714318A2 (pt) Utilização de 2-benzoil-imidazopiridinas em terapêutica
PT1763520E (pt) Utilização de benzopiranonas trissubstituídas
BRPI0811572A2 (pt) Uso de compostos imunomoduladores no tratamento de doenças alérgicas
EP1864662A4 (en) THERAPEUTIC AGENT AGAINST THROMBOSE
DE602006000763D1 (de) Kissenkörper
BRPI0714307A2 (pt) Uso de benzamidas trifluormetil-substituídas no tratamento de distúrbios neurológicos
DE602005005655D1 (de) Massagebett
FI20050453A0 (fi) Ihonhoitokoostumus
NO20051756D0 (no) Stol
NO20065018A (no) Stol
EP2050454A4 (en) MOISTURIZING AGENT